אלוריל 300 ישראל - עברית - Ministry of Health

אלוריל 300

dexcel ltd, israel - allopurinol - טבליה - allopurinol 300 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

אלוריל 100 ישראל - עברית - Ministry of Health

אלוריל 100

dexcel ltd, israel - allopurinol - טבליה - allopurinol 100 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

פרינג'קט ישראל - עברית - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial - ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. the diagnosis must be based on laboratory tests.

פרינג'קט ישראל - עברית - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial

פרינג'קט ישראל - עברית - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial

פרינג'קט ישראל - עברית - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial

סודיום כלוריד % 0.9 לעירוי לתוך הוריד BP ישראל - עברית - Ministry of Health

סודיום כלוריד % 0.9 לעירוי לתוך הוריד bp

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

סודיום כלוריד % 0.9 לעירוי לתוך הוריד BP ישראל - עברית - Ministry of Health

סודיום כלוריד % 0.9 לעירוי לתוך הוריד bp

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

יאז ישראל - עברית - Ministry of Health

יאז

bayer israel ltd - drospirenone; ethinylestradiol - טבליות מצופות פילם - drospirenone 3 mg; ethinylestradiol 0.02 mg - drospirenone and estrogen - drospirenone and estrogen - - oral contraception. - treatment of moderate acne vulgaris in women who seek oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd ) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms ( premenstrual syndrome ).

אוולטרה  ישראל - עברית - Ministry of Health

אוולטרה

sanofi israel ltd - clofarabine - תרכיז להכנת תמיסה לאינפוזיה - clofarabine 1 mg/ml - clofarabine - clofarabine - treatment of acute lymphoblastic leukaemia (all) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and who are about to undergo transplantation. safety and efficacy have been assessed in studies of patients < or = 21 years old at initial diagnosis .